GlobeNewswire

Blockchain World Conference to Make History as Largest Crypto Event Ever Held

Dela

With 8,000+ attendees and 120+ exhibitors now expected, Blockchain World Conference will be the largest-ever conference in the crypto space by all measures

ATLANTIC CITY, N.J., June 11, 2018 (GLOBE NEWSWIRE) -- via CryptoCurrencyWire - Blockchain World Conference, a global brand committed to producing the highest quality crypto-oriented events, today announces its tremendous success in securing an unprecedent number of accredited investors and powerful list of world-renowned speakers for the upcoming Blockchain World Conference. Produced by BWC Events this three-day conference is scheduled for July 11-13, 2018, and it will take place at the world-famous Harrah's Resort in Atlantic City, NJ.

Blockchain World Conference brings together the most compelling lineup of blockchain and crypto experts ever to unite in a single event. Industry experts, scientists, analysts, educators and leaders will appear on stage for the biggest and most transformative blockchain industry event the world has ever seen.

At Blockchain World Conference, attendees will have the unique opportunity to:

  • Meet and greet with leading blockchain developers
  • Network with blockchain enthusiasts, investors and businesses
  • Learn about the future of blockchain development
  • Discover blockchain startups and businesses utilizing ICO crowdfunding
  • Hear how to increase the security of crypto-assets
  • And much more!

The event will be packed with presentations, panel discussions, educational seminars, industry addresses, invaluable networking events, exhibits and more. The conference will be capped by a keynote address delivered by "the bad boy of blockchain," John McAfee. Unforgettable fun will also be woven in throughout the three-day conference with VIP suite parties, golf outings, dance parties and much more. Take advantage of life-changing networking opportunities as you enjoy the sites and sounds of the exciting Atlantic City!

"There is simply nowhere else on earth where you can learn more and gain more than at the Blockchain World Conference," said Alex Falcone, Chief Operating Officer of Blockchain World Conference. "Don't miss this once-in-a-lifetime opportunity to be part of blockchain history as the world's best and brightest blockchain and fintech leaders come together. With just over a month to go before the event, thousands of tickets have already been sold and full sellout is imminent. Don't miss this opportunity!"

Blockchain World Conference anticipates featuring more than 120 exhibitors housed in 50,000 square feet of exhibit space. More than 8,000 attendees are expected representing over 42 countries, and more than 25,000 global viewers will also tune in for live streaming.

Special Discount for Live Streaming Worldwide and On-Site Attendance

To save 10% on any ticket, including VIP, use the following hyperlink: 10% OFF Blockchain World Conference (or enter promo code CRYPTOBWC at checkout).

Additional information about the conference can be found at www.BWCevent.com

About BWC Events

BWC Events recognizes that the brave new world of blockchain is evolving at a breakneck pace and that the technology behind blockchain itself has the potential to touch, and significantly impact, virtually every imaginable human endeavor.

This event organizer firmly believes an industry united is an industry strong and that the blockchain industry will benefit greatly from improved cohesiveness of collective mindset. BWC Events aims to grow the global acceptance of blockchain technologies by creating and enhancing awareness of the benefits of blockchain and by growing the reach and breadth of crypto awareness. Everyone is welcomed to join the growing movement to bring blockchain to new heights of awareness and to extend its reach far into new areas of society and industry.

BWC Events
www.BWCevent.com 
Philadelphia, Pennsylvania 
info@BWCevent.com
657.464.7195 Office

Corporate Communications Contact
CryptoCurrencyWire (CCW)
New York, New York
www.CryptoCurrencyWire.com
212.418.1217 Office
Editor@CryptoCurrencyWire.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BWC Events via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum